As AbbVie’s Crohn’s combo beats Skyrizi in mid-stage test, analysts laud autoimmune vision

AbbVie’s next-gen dual-targeting therapy elicited higher rates of remission than its IL-23 inhibitor Skyrizi in a Phase 2a trial of Crohn’s disease, leading analysts to wonder if the blockbuster can be outdone.